New cell therapy trial offers hope for tough blood cancers
Disease control
Recruiting now
This study is testing an experimental cell therapy called CTD402 for people aged 12 and older whose T-cell leukemia or lymphoma has come back or hasn't responded to other treatments. Participants receive a single infusion of these specially modified immune cells and are then moni…
Phase: PHASE1, PHASE2 • Sponsor: BIOHENG THERAPEUTICS US LLC • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC